Abstract
Mass spectrometry biomarker discovery may assist patients diagnosis in time and realize the characteristics of new diseases. Our previous work built a preprocess method called HHTmass which is capable of removing noise, but HHTmass only a proof of principle to be peak detectable and did not tested for peak reappearance rate and used on medical data. We developed a modified version of biomarker discovery method called Enhance HHTMass (E-HHTMass) for MALDI-TOF and SELDI-TOF mass spectrometry data which improved old HHTMass method by removing the interpolation and the biomarker discovery process. E-HHTMass integrates the preprocessing and classification functions to identify significant peaks. The results show that most known biomarker can be found and high peak appearance rate achieved comparing to MSCAP and old HHTMass2. E-HHTMass is able to adapt to spectra with a small increasing interval. In addition, new peaks are detected which can be potential biomarker after further validation.
Keywords: Biomarker discovery, Hilbert-Huang transform, MALDI-TOF, Mass spectrometry, SELDI-TOF, HHTmass, MASCAP, Nephrological disease, Urinary hepcidin, Oral cancer:, SpecAlign, Denoising, WEKA, GUI
Protein & Peptide Letters
Title: Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform
Volume: 19 Issue: 1
Author(s): Li-Ching Wu, Ping-Heng Hsieh, Jorng-Tzong Horng, Yu-Jen Jou, Chia-Der Lin, Kuang-Fu Cheng, Cheng-Wen Lin and Shih-Yin Chen
Affiliation:
Keywords: Biomarker discovery, Hilbert-Huang transform, MALDI-TOF, Mass spectrometry, SELDI-TOF, HHTmass, MASCAP, Nephrological disease, Urinary hepcidin, Oral cancer:, SpecAlign, Denoising, WEKA, GUI
Abstract: Mass spectrometry biomarker discovery may assist patients diagnosis in time and realize the characteristics of new diseases. Our previous work built a preprocess method called HHTmass which is capable of removing noise, but HHTmass only a proof of principle to be peak detectable and did not tested for peak reappearance rate and used on medical data. We developed a modified version of biomarker discovery method called Enhance HHTMass (E-HHTMass) for MALDI-TOF and SELDI-TOF mass spectrometry data which improved old HHTMass method by removing the interpolation and the biomarker discovery process. E-HHTMass integrates the preprocessing and classification functions to identify significant peaks. The results show that most known biomarker can be found and high peak appearance rate achieved comparing to MSCAP and old HHTMass2. E-HHTMass is able to adapt to spectra with a small increasing interval. In addition, new peaks are detected which can be potential biomarker after further validation.
Export Options
About this article
Cite this article as:
Wu Li-Ching, Hsieh Ping-Heng, Horng Jorng-Tzong, Jou Yu-Jen, Lin Chia-Der, Cheng Kuang-Fu, Lin Cheng-Wen and Chen Shih-Yin, Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform, Protein & Peptide Letters 2012; 19 (1) . https://dx.doi.org/10.2174/092986612798472929
DOI https://dx.doi.org/10.2174/092986612798472929 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vitamin D and Cancer Mortality: Systematic Review of Prospective Epidemiological Studies
Anti-Cancer Agents in Medicinal Chemistry Characterization of Cancer Stem Cells and Primary Cilia in Medulloblastoma
CNS & Neurological Disorders - Drug Targets Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases
Current Drug Targets Current Advances in Therapy for Metastatic Melanoma
Current Cancer Therapy Reviews MDM2 Inhibitors for Pancreatic Cancer Therapy
Mini-Reviews in Medicinal Chemistry Recent Progress in Medicinal Investigations on Trichosanthin and other Ribosome Inactivating Proteins from the Plant Genus Trichosanthes
Current Medicinal Chemistry Exploiting Innate γδ T Lymphocytes for Tumor Immunotherapy
Recent Patents on Biomarkers Current Therapeutics, Their Problems and Thiol Metabolism as Potential Drug Targets in Leishmaniasis
Current Drug Metabolism Cationic Lipophilic Radiotracers for Functional Imaging of Multidrug Resistance
Current Radiopharmaceuticals Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Current Cancer Drug Targets Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View
Current Cancer Drug Targets Silicon Switches of Marketed Drugs
Mini-Reviews in Medicinal Chemistry Anti-VEGF Mediated Immunomodulatory Role of Phytochemicals: Scientific Exposition for Plausible HCC Treatment
Current Drug Targets Distinct Epigenetic Reprogramming, Mitochondrial Patterns, Cellular Morphology, and Cytotoxicity after Bee Venom Treatment
Recent Patents on Anti-Cancer Drug Discovery HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer
Current Signal Transduction Therapy Lack of Association between miR-605 rs2043556 Polymorphism and Overall Cancer Risk: A Meta-analysis of Case-control Studies
MicroRNA Cancer and Stem Cells
Current Cancer Therapy Reviews Synthesis, Cytotoxic Evaluation, and Molecular Docking Studies of New Oxadiazole Analogues
Letters in Organic Chemistry Dietary Habits of Mongolian People, and Their Influence on Lifestyle-Related Diseases and Early Aging
Current Aging Science